Auszug aus der Pressemitteilung zum Ergebnis des 2. Quartals :
XOMA had $71.8 million in cash, cash equivalents and short-term investments as of June 30, 2001, compared with $35.2 million at December 31, 2000. XOMA completed an underwritten equity offering in June 2001, selling 3.0 million common shares for net proceeds of $43.3 million.
``This has been an exciting and eventful quarter for XOMA,`` said Jack Castello, XOMA`s chairman, president and chief executive officer. ``The highlight was the presentation at scientific meetings of data from the two pivotal Phase III trials testing Xanelim(TM) in moderate-to-severe psoriasis patients. All primary and secondary efficacy endpoints were met in both trials, and we are working with our partner Genentech to prepare the BLA filing, pending favorable results after further data analysis. We also substantially strengthened the Company`s financial position with a successful $43 million equity offering in June.``
``Our second quarter financial results were in line with our expectations,`` said Peter B. Davis, XOMA`s chief financial officer. ``For the full year 2001, our current expectation is that the Company`s loss will be somewhat lower than in 2000, as higher revenues will more than offset higher expenses. Following our recent equity offering, based on current spending levels, we believe that XOMA`s cash resources are sufficient to meet currently anticipated needs for at least the next three years.``
|aus der Diskussion:||XOMA: Neueste Quartalszahlen|
|Autor (Datum des Eintrages):||BigLinus (09.08.01 23:59:35)|
|Beitrag:||2 von 6 (ID:4171516)|
|Alle Angaben ohne Gewähr © wallstreet:online|